Glycosylation alterations have been associated with the development of several human diseases and their animal models, including multiple sclerosis.
Objectives:
We aimed to determine whether immunoglobulin G galactosylation might be changed in multiple sclerosis.
Methods:
Immunoglobulin G was isolated from serum and cerebrospinal fluid of patients with multiple sclerosis or viral meningitis and control patients without history of inflammatory or autoimmune disease. A lectin-based assay was used to investigate potential galactosylation modifications of immunoglobulin G.
Results and conclusion:
Galactosylation of immunoglobulin G isolated from cerebrospinal fluid of control patients was found to be age- and gender-dependent. In addition, immunoglobulin G galactosylation was significantly altered in cerebrospinal fluid but not in serum of multiple sclerosis patients. Furthermore, this modification was correlated with an active progression of multiple sclerosis. Finally, the loss of galactosyl moieties was not simply associated with inflammation as no such change was detected in viral meningitis patients characterized by brain inflammation.
MariñoKBonesJKattlaJJ. et al. A systematic approach to protein glycosylation analysis: A path through the maze. Nat Chem Biol2010; 6: 713–723.
2.
BrynedalBWojcikJEspositoF. et al. MGAT5 alters the severity of multiple sclerosis. J Neuroimmunol2010; 220: 120–124.
3.
AlverezKHaswellCSt ClairM. et al. Sequences of the mouse N-acetylglucosaminyltransferase V (Mgat5) mRNA and an mRNA expressed by an Mgat5-deficient cell line. Glycobiology2002; 12: 389–394.
4.
DemetriouMGranovskyMQuagginS. et al. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature2001; 409: 733–739.
5.
LeeSUGrigorianAPawlingJ. et al. N-glycan processing deficiency promotes spontaneous inflammatory demyelination and neurodegeneration. J Biol Chem2007; 282: 33725–33734.
6.
DwekRA. Glycobiology: Toward understanding the function of sugars. Chem Rev1996; 96: 683–720.
7.
HuhnCSelmanMHRuhaakLR. et al. IgG glycosylation analysis. Proteomics2009; 9: 882–913.
8.
ParekhRBDwekRASuttonBJ. et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature1985; 316: 452–457.
9.
Van ZebenDRookGAHazesJM. et al. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: Results of a follow-up study. Br J Rheumatol1994; 33: 36–43.
10.
Dall’OlioFVanhoorenVChenCC. et al. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ageing Res Rev2013; 12: 685–698.
11.
ObermeierBMenteleRMalotkaJ. et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med2008; 14: 688–693.
12.
PolmanCHReingoldSCBanwellB. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
13.
PasekMDukMPodbielskaM. et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients–Changes during therapy. Glycoconj J2006; 23: 463–471.
14.
TsuchiyaNEndoTMatsutaK. et al. Detection of glycosylation abnormality in rheumatoid IgG using N-acetylglucosamine-specific Psathyrella velutina lectin. J Immunol1993; 151: 1137–1146.
15.
ReiberHUngefehrSJacobiC. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler1998; 4: 111–117.
16.
AbèsRTeillaudJ-L. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals2010; 3: 146–157.
17.
SumarNBodmanKBRademacherTW. et al. Analysis of glycosylation changes in IgG using lectins. J Immunol Methods1990; 131: 127–136.
18.
SumarNIsenbergDABodmanKB. et al. Reduction in IgG galactose in juvenile and adult onset rheumatoid arthritis measured by a lectin binding method and its relation to rheumatoid factor. Ann Rheum Dis1991; 50: 607–610.
19.
RoutierFHHounsellEFRuddPM. et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: A critical evaluation of different methods. J Immunol Methods1998; 213: 113–130.
20.
BondAJonesMGHayFC. Human IgG preparations isolated by ion-exchange or protein G affinity chromatography differ in their glycosylation profiles. J Immunol Methods1993; 166: 27–33.
21.
EiselePSzaboKGriebeM. et al. Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion. Mult Scler2014; 20: 1391–1395.
22.
AlbrechtSUnwinLMuniyappaM. et al. Glycosylation as a marker for inflammatory arthritis. Cancer Biomark2014; 14: 17–28.
23.
AnthonyRMWermelingFRavetchJV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci2012; 1253: 170–180.
24.
BondtARomboutsYSelmanMH. et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics2014; 13: 3029–3039.
25.
ParekhRBDwekRARademacherTW. Rheumatoid arthritis as a glycosylation disorder. Br J Rheumatol1988; 27(Suppl. 2): 162–169.
26.
YouingsAChangSCDwekRA. et al. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J1996; 314(Pt 2): 621–630.
27.
RademacherTWWilliamsPDwekRA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci U S A1994; 91: 6123–6127.
28.
MalhotraRWormaldMRRuddPM. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med1995; 1: 237–243.
29.
NakajimaSIijimaHShinzakiS. et al. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis2011; 17: 927–936.
30.
WuhrerMSelmanMHMcDonnellLA. et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation2015; 12: 235.
